Sangamo Therapeutics Inc
NASDAQ:SGMO
Intrinsic Value
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. [ Read More ]
The intrinsic value of one SGMO stock under the Base Case scenario is 1.9809 USD. Compared to the current market price of 0.6702 USD, Sangamo Therapeutics Inc is Undervalued by 66%.
Valuation Backtest
Sangamo Therapeutics Inc
Run backtest to discover the historical profit from buying and selling SGMO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Significant Advances and Financial Prudence
2023-Q4 Earnings Call
The company has preclinical models suggesting a breakthrough in treating diseases like prion and tauopathies such as Alzheimer's, with the potential to extend life. They plan to submit a clinical trial authorization (CTA) in the UK in Q4 2025 due to its robust prion disease infrastructure. Additionally, a resumption of their tau program is anticipated, also in Q4 2025, aiming at disorders like Parkinson's. Financially, they've slashed operational spending by half, ending 2023 with $81 million, sufficient to last into Q3 2024. They forecast operating expenses for 2024 to be between $125 million and $145 million, decreasing to below $105 million in 2025. Advanced capsid STAC-BBB outshines others by a notable 700-fold in brain enrichment, vital for treating neurological disorders.
Balance Sheet Decomposition
Sangamo Therapeutics Inc
Current Assets | 94.3m |
Cash & Short-Term Investments | 81m |
Receivables | 1.3m |
Other Current Assets | 12m |
Non-Current Assets | 71m |
PP&E | 52.9m |
Other Non-Current Assets | 18.1m |
Current Liabilities | 47.7m |
Accounts Payable | 15.3m |
Accrued Liabilities | 32.5m |
Non-Current Liabilities | 34.7m |
Other Non-Current Liabilities | 34.7m |
Earnings Waterfall
Sangamo Therapeutics Inc
Revenue
|
176.2m
USD
|
Operating Expenses
|
-278.8m
USD
|
Operating Income
|
-102.6m
USD
|
Other Expenses
|
-155.2m
USD
|
Net Income
|
-257.8m
USD
|
Free Cash Flow Analysis
Sangamo Therapeutics Inc
What is Free Cash Flow?
SGMO Profitability Score
Profitability Due Diligence
Sangamo Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
Score
Sangamo Therapeutics Inc's profitability score is 16/100. The higher the profitability score, the more profitable the company is.
SGMO Solvency Score
Solvency Due Diligence
Sangamo Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Sangamo Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SGMO Price Targets Summary
Sangamo Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for SGMO is 3.23 USD with a low forecast of 1.01 USD and a high forecast of 8.4 USD.
Ownership
SGMO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SGMO Price
Sangamo Therapeutics Inc
Average Annual Return | -7.69% |
Standard Deviation of Annual Returns | 70.59% |
Max Drawdown | -98% |
Market Capitalization | 119.4m USD |
Shares Outstanding | 178 906 000 |
Percentage of Shares Shorted | 6.61% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. The company is headquartered in Brisbane California, California and currently employs 431 full-time employees. The company went IPO on 2000-04-06. The firm focuses on leveraging its optimized zinc finger (ZF) technology, which is a differentiated tool used to develop genomic medicines, including allogeneic cell therapies and in vivo genome engineering therapies. Its product candidates include Isaralgagene civaparvovec, also known as ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease; SAR445136, its ZF nuclease, gene-edited cell therapy product candidate for the treatment of sickle cell disease (SCD); TX200, its wholly owned Chimeric Antigen Receptor (CAR) engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; Giroctocogene fitelparvovec, also known as SB-525, is a gene therapy product candidate for the treatment of moderately severe to severe hemophilia A.
Contact
IPO
Employees
Officers
The intrinsic value of one SGMO stock under the Base Case scenario is 1.9809 USD.
Compared to the current market price of 0.6702 USD, Sangamo Therapeutics Inc is Undervalued by 66%.